Vesselon's TriForm Platform Delivers 6-Fold More Antibody Drug to Tumors While Reducing Off-Target Exposure
核心洞察
Vesselon (搜索) received U.S. Patent No. 12,714,676 for a co-formulation platform combining microspheres, liposomes, and therapeutic antibodies to enhance tumor-specific drug delivery.
The FDA-approved Imagent-based TriForm platform delivered approximately 6 times more drug to targeted tumors while reducing off-target uptake that can cause toxicity.
Among 29 solid-tumor categories, 27 had objective response rates below 25% for checkpoint inhibitor monotherapy, underscoring the unmet need the platform addresses.
The U.S. Patent and Trademark Office has issued U.S. Patent Number 12,714,676 to Vesselon (搜索), titled "COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTICS USING CARRIERS," describing a composition that includes microspheres, liposomes, and therapeutic antibodies. The platform enables biologics—particularly monoclonal antibodies—to be co-formulated on-site to create microbubble/liposome complexes capable of enhancing tumor-specific delivery while reducing systemic exposure in combination with ultrasound activation. The formulation delivers approximately 6 times more drug to a targeted tumor while reducing off-target uptake that can cause toxicity.
The clinical significance of this advance is underscored by the current limitations of antibody-based therapies. A large percentage of patients on checkpoint inhibitor, antibody drug conjugate (ADC), and bispecific drugs must reduce dose, discontinue treatment, or obtain little clinical benefit from treatments that cost hundreds of thousands of dollars. Among 29 solid-tumor categories, 27 had patient objective response rates below 25% for checkpoint inhibitor monotherapy.
Preclinical Evidence of Enhanced Delivery
In a recent journal article published this May, researchers demonstrated the ability of Vesselon (搜索)'s FDA-approved microsphere and liposome co-formulation to augment the delivery of the mouse-equivalent of Keytruda to tumors 6-fold while dramatically reducing the monoclonal antibody exposure to other organs.
"Our findings demonstrate that Vesselon (搜索)'s co-formulation enhances intratumoral delivery of checkpoint inhibitors, improves survival, and reduces systemic organ exposure, representing a promising platform to improve the efficacy and safety profile of antibody-based immunotherapy," stated Pier Paolo Claudio, MD, PhD, Professor of Pharmacology & Toxicology at the University of Mississippi Medical Center and the Cancer Center & Research Institute.
The TriForm Platform and Its Mechanism
Vesselon (搜索) refers to the co-formulation as TriForm. The on-site, in-vial mixing process instantly combines a therapeutic drug with its Imagent proprietary lipid microspheres. The FDA approval for Imagent included 67 clinical and preclinical studies validating the safety level of saline. After mixing a standard dose, each vial contains approximately 10 billion lipid microspheres encapsulating the active drug, 50 trillion liposomes loaded with the active drug, as well as the freely circulating drug.
Vesselon (搜索) President and CEO Clay Larsen commented on the industry-changing potential of this platform: "Pharmaceutical manufacturers spend billions in R&D on the biochemistry of their drugs. We employ biophysics to more effectively deliver life-saving drugs to tumors, with the promise of less side effects to the patients' health profile as a whole. With this one platform, we can elevate the therapeutic index of whole classes of antibodies for either new drugs or the many blockbusters facing patent expiration."
Any pharmaceutical agent combined with the TriForm platform becomes a new chemical entity that is patentable as well, positioning the technology to extend patents and create a stream of proprietary drugs.